{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:08:06Z","timestamp":1759482486762},"reference-count":19,"publisher":"American Society of Consultant Pharmacists","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2014,1,1]]},"DOI":"10.4140\/tcp.n.2014.47","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T21:06:26Z","timestamp":1389387986000},"page":"47-52","source":"Crossref","is-referenced-by-count":2,"title":["A Case-Based Approach to Evaluating Azithromycin Use and Cardiovascular Risks"],"prefix":"10.4140","volume":"29","author":[{"given":"Elaine","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy V.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1753465810381518","article-title":"Management of community-acquired pneumonia","volume":"5","author":"NK Brar","year":"2011","journal-title":"Ther Adv Resp Dis"},{"key":"2","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"LA Mandall","year":"2007","journal-title":"Clin Infect Dis"},{"key":"3","unstructured":"CDC. Pneumonia can be prevented \u2013 vaccines can help. Available at www.cdc.gov\/features\/pneumonia. Accessed March 8, 2013. <a target=\"_blank\" href='http:\/\/www.cdc.gov\/features\/pneumonia'>www.cdc.gov\/features\/pneumonia<\/a>"},{"key":"4","unstructured":"IMS Institute for Healthcare Informatics. The use of medicines in the United States review of 2011. Available at http:\/\/www.imshealth.com\/ims\/Global\/Content\/Insights\/IMS%20Institute%20for%20Healthcare%20Informatics\/IHII_Medicines_in_U.S_Report_2011.pdf. Accessed February 28, 2013. <a target=\"_blank\" href='http:\/\/www.imshealth.com\/ims\/Global\/Content\/Insights\/IMS%20Institute%20for%20Healthcare%20Informatics\/IHII_Medicines_in_U.S_Report_2011.pdf'>http:\/\/www.imshealth.com\/ims\/Global\/Content\/Insights\/IMS%20Institute%20for%20Healthcare%20Informatics\/IHII_Medicines_in_U.S_Report_2011.pdf<\/a>"},{"key":"5","unstructured":"Zithromax (azithromycin) tablets and oral suspension [prescribing information]. New York, NY: Pfizer Labs; 2013."},{"key":"6","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of CV death","volume":"366","author":"WA Ray","year":"2012","journal-title":"N Engl J Med"},{"key":"7","unstructured":"Micromedex Healthcare Series [internet database]. Greenwood Village, CO: Thomson Healthcare; updated periodically. Accessed March 21, 2013."},{"key":"8","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1086\/508873","article-title":"Antimicrobial-associated QT prolongation: pointes of interest","volume":"43","author":"RC Owens","year":"2006","journal-title":"Clin Infect Dis"},{"key":"9","unstructured":"Food and Drug Administration. FDA Statement regarding azithromycin (Zithromax) and the risk of CV death [05-17-2012]. Available at http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm304372.htm. Accessed March 15, 2013. <a target=\"_blank\" href='http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm304372.htm'>http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm304372.htm<\/a>"},{"key":"10","unstructured":"Food and Drug Administration. FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms [3-12-2013]. Available at http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm341822.Htm. Accessed March 15, 2013. <a target=\"_blank\" href='http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm341822.Htm'>http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm341822.Htm<\/a>"},{"key":"11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ahj.2007.01.040","article-title":"Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes","volume":"153","author":"A Gupta","year":"2007","journal-title":"Am Heart J"},{"key":"12","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"YG Yap","year":"2003","journal-title":"Heart"},{"key":"13","unstructured":"Dolophine hydrochloride CII (methadone hydrochloride tablets, USP) [prescribing information]. Columbus, OH: Roxane Laboratories, Inc.; 2006. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/006134s028lbl.pdf. Accessed April 18, 2013. <a target=\"_blank\" href='http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/006134s028lbl.pdf'>http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/006134s028lbl.pdf<\/a>"},{"key":"14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7326\/0003-4819-137-6-200209170-00010","article-title":"Torsade de pointes associated with very-high-dose methadone","volume":"137","author":"MJ Krantz","year":"2002","journal-title":"Ann Intern Med"},{"key":"15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(06)69173-3","article-title":"QTc prolongation: methadone's efficacysafety paradox","volume":"368","author":"MJ Krantz","year":"2006","journal-title":"Lancet"},{"key":"16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2146\/ajhp070392","article-title":"Methadone-associated Q-T prolongation and torsades de pointes","volume":"66","author":"JS Stringer","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"17","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death","volume":"158","author":"AH Glassman","year":"2001","journal-title":"Am J Psychiatry"},{"key":"18","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1161\/01.CIR.0000145144.56673.59","article-title":"Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical Care Nurses","volume":"110","author":"BJ Drew","year":"2004","journal-title":"Circulation"},{"key":"19","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"On behalf of the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, the Council on Cardiovascular Nursing, and the American College of Cardiology Foundation. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"121","author":"BJ Drew","year":"2010","journal-title":"Circulation"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T01:52:49Z","timestamp":1498096369000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2014\/00000029\/00000001\/art00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1,1]]}},"alternative-id":["Y1N740J60537X102"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2014.47","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,1]]}}}